Evaluation of Impaired Mobility in Chronic Illness Constitution of a Cohort

Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Chronic illness is a public health issue and mobility loss is frequent in this population. Among its' multiple physical and psychological consequences, increased mortality and cardiovascular morbidity seem the main concern. Therefore, the exploration of locomotor deficiencies, physical capacities and metabolism of patients with chronic illnesses constitutes a major challenge both for the treatment of causal pathologies, as well as for evaluating the impact of therapeutic interventions, the benefit of which will be an improvement in physical capacities and ultimately mobility. In view of the hypothesis of an increase in the prevalence of mobility disorders in this population, this approach is part of a logic of screening and improving the effectiveness of the care of these patients with a multidisciplinary evaluation of individual risks. The EVALMOB protocol was designed in order to try to determine a standard profile of dysmobility in patients with chronic illness

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 90
Healthy Volunteers: f
View:

• Man or woman aged 18 to 90.

• Patients with chronic pathology contributing to impaired mobility.

• Volunteers who have given their written consent.

• Affiliated to French health care system (for France)

Locations
Other Locations
France
Chu Clermont Ferrand
RECRUITING
Clermont-ferrand
Contact Information
Primary
Lise Laclautre
promo_interne_drci@chu-clermontferrand.fr
334.73.754.963
Time Frame
Start Date: 2020-08-27
Estimated Completion Date: 2035-08-26
Participants
Target number of participants: 5000
Treatments
Experimental: Cohort 1
Participants will be involved in a long-term evaluation program combining, body composition measures, physical tests as well as self-administered questionnaires. Participants will be followed for 5 years with evaluations taking place at inclusion, 6 months, at 1, 2 and 5 years
Sponsors
Leads: University Hospital, Clermont-Ferrand
Collaborators: I-SITE Cap 20-25 project

This content was sourced from clinicaltrials.gov